Aggarwal M, Singh J, Sood S, Arora B
Departments of Pharmacology, Physiology and Pathology, Post Graduate Institute of Medical Sciences, Rohtak, India.
Methods Find Exp Clin Pharmacol. 2001 Apr;23(3):131-4. doi: 10.1358/mf.2001.23.3.627945.
Streptozotocin (STZ)-induced diabetic neuropathy in rats was monitored by measuring the motor nerve conduction velocity (MNCV) and histopathology of the tibial nerve. Pretreatment with lisinopril (2 mg/kg p.o., 5 days prior to STZ and continued for 10 weeks) significantly (p < 0.01) prevented deterioration of MNCV as compared to STZ-diabetic animals. Nerve sections from the lisinopril pretreated group revealed less structural damage as compared to STZ-diabetic rats. However lisinopril had no effect on blood sugar, i.e., it did not alter the diabetic state. It is concluded that lisinopril prevents the development of experimental diabetic neuropathy in STZ-induced diabetic rats.
通过测量大鼠胫神经的运动神经传导速度(MNCV)和组织病理学来监测链脲佐菌素(STZ)诱导的糖尿病性神经病变。与STZ诱导的糖尿病动物相比,赖诺普利预处理(2mg/kg口服,在STZ给药前5天开始并持续10周)显著(p<0.01)预防了MNCV的恶化。与STZ诱导的糖尿病大鼠相比,赖诺普利预处理组的神经切片显示结构损伤较轻。然而,赖诺普利对血糖没有影响,即它没有改变糖尿病状态。结论是,赖诺普利可预防STZ诱导的糖尿病大鼠实验性糖尿病性神经病变的发展。